Huub Schellekens | Writers Unlimited
PDF) Immunogenicity of Recombinant Human Interferon Beta-1b in Immune-Tolerant Transgenic Mice Corresponds with the Biophysical Characteristics of Aggregates
Biosimilars bieden oplossing voor stijgende kost onco- en hematologische behandelingen - Actualiteit - Belgian Oncology & Hematology News - Artsenkrant.com
Professor Schellekens maakt medicijnen zelf - Zembla - BNNVARA
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Immunogenicity and glycosylation: The key issues for biosimilars - ppt video online download
Catalogus Professorum - Prof Detail
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
BIOLOGICALS UIT DE BIO-NESPRESSO?
Over regulering van angst – Studium Generale Universiteit Utrecht
SciELO - Saúde Pública - Hubs to spread technology and save lives Hubs to spread technology and save lives
Heidi Schellekens - massage & bewustwording Utrecht | Utrecht
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
Huub Schellekens – Studium Generale Universiteit Utrecht
Huub Schellekens | European Association of Hospital Pharmacists
Huub Schellekens - HR Business Partner - Feenstra | LinkedIn
Huub Schellekens's research works | Utrecht University, Utrecht (UU) and other places
Protection of Rats against Pseudorabies Virus Infection by γ-Interferon
eLearning module: The analytics – Biosimilars: From concern to confidence
Pharmaceutical Technology Europe - August 2010 - What is Hindering the Uptake of Biosimilars
PDF) Making individualized drugs a reality
PDF) Immunogenicity of mAbs in non-human primates during nonclinical safety assessment | Beatriz Silva Lima - Academia.edu
Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations
PDF) Biosimilar therapeutics—What do we need to consider?
Zo kan Nederland zich beter wapenen tegen epidemieën
